LUCENTIS (ranibizumab)

OFFICE ADMINISTRATION - Sterile Environment / Aseptic Technique

Indications for Prior Authorization:

  • Neovascular (WET) age related Macular Degeneration (AMD)
  • Macular edema secondary to retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Combination therapy with verteporfin (Visudyne®)
  • Any other diagnosis not listed in the approved indications

Dosing:

  • The dose of ranibizumab for AMD and RVO is not to exceed 0.5 mg (five units) once a month (28 days) by intravitreous injection.
  • The dose for DME is 0.3 mg once a month (28 days)

Monitoring:

  • Elevation in intraocular pressure
  • Ocular inflammation (endophthalmitis)
    • Immediately after injection check for perfusion of the optic nerve head
    • Measure intraocular pressure (tonometry) within 30 minutes following injection
    • Slit lamp biomicroscopy between 2 and 7 days following injection

 

Last review date: December 2, 2013

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone